Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).

Emons G, Gorchev G, Sehouli J, Wimberger P, Stähle A, Hanker L, Hilpert F, Sindermann H, Gründker C, Harter P.

Gynecol Oncol. 2014 Jun;133(3):427-32. doi: 10.1016/j.ygyno.2014.03.576. Epub 2014 Apr 5.

PMID:
24713545
2.

AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.

Engel J, Emons G, Pinski J, Schally AV.

Expert Opin Investig Drugs. 2012 Jun;21(6):891-9. doi: 10.1517/13543784.2012.685128. Review.

PMID:
22577891
3.

A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.

Rose PG, Smrekar M, Haba P, Fusco N, Rodriguez M.

Am J Clin Oncol. 2008 Oct;31(5):476-80. doi: 10.1097/COC.0b013e31816a6221.

PMID:
18838885
4.

Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer.

Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK.

Clin Cancer Res. 2014 Dec 15;20(24):6277-83. doi: 10.1158/1078-0432.CCR-14-0489. Epub 2014 Oct 2.

5.

Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).

Emons G, Gorchev G, Harter P, Wimberger P, Stähle A, Hanker L, Hilpert F, Beckmann MW, Dall P, Gründker C, Sindermann H, Sehouli J.

Int J Gynecol Cancer. 2014 Feb;24(2):260-5. doi: 10.1097/IGC.0000000000000044.

6.

A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.

Nakanishi T, Aoki D, Watanabe Y, Ando Y, Tomotsugu N, Sato Y, Saito T.

Jpn J Clin Oncol. 2015 May;45(5):422-6. doi: 10.1093/jjco/hyv016. Epub 2015 Feb 10.

PMID:
25670764
7.

Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.

Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P.

J Clin Oncol. 2012 Nov 1;30(31):3841-7. doi: 10.1200/JCO.2011.38.8082. Epub 2012 Sep 17.

PMID:
22987083
8.

Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.

Katsumata N, Fujiwara Y, Kamura T, Nakanishi T, Hatae M, Aoki D, Tanaka K, Tsuda H, Kamiura S, Takehara K, Sugiyama T, Kigawa J, Fujiwara K, Ochiai K, Ishida R, Inagaki M, Noda K.

Jpn J Clin Oncol. 2008 Nov;38(11):777-85. doi: 10.1093/jjco/hyn101. Epub 2008 Oct 16.

9.

Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.

Goto T, Takano M, Ohishi R, Iwasa N, Shimizu M, Hasegawa K, Nagao S, Fujiwara K.

J Obstet Gynaecol Res. 2010 Aug;36(4):764-8. doi: 10.1111/j.1447-0756.2010.01217.x.

PMID:
20666942
10.

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.

Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, Sood AK, Coleman RL, Gershenson DM.

Gynecol Oncol. 2012 Jun;125(3):640-5. doi: 10.1016/j.ygyno.2012.02.034. Epub 2012 Feb 28.

PMID:
22387451
11.

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.

Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J.

Gynecol Oncol. 2000 Sep;78(3 Pt 1):369-72.

PMID:
10985896
12.
13.

Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.

Safra T, Berman T, Yachnin A, Bruchim I, Meirovitz M, Barak F, Atlas I, Levy T, Rosengarten OS.

Int J Gynecol Cancer. 2013 Mar;23(3):475-80. doi: 10.1097/IGC.0b013e3182866944.

PMID:
23435437
14.

Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.

Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM.

J Clin Oncol. 2003 Jan 15;21(2):291-7.

PMID:
12525521
15.

Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.

Gorumlu G, Kucukzeybek Y, Kemal-Gul M, Karaca B, Cosan-Terek M, Karabulut B, Sanli UA, Akman L, Ozsaran A, Dikmen Y, Uslu R.

J BUON. 2008 Jul-Sep;13(3):349-52.

PMID:
18979548
16.

An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.

Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D, Katsaros D, Sessa C, Rinaldi A, Bertoni F, Vitali A, Catapano CV, Marsoni S, van de Velde H, Colombo N.

Int J Gynecol Cancer. 2012 Jun;22(5):792-800. doi: 10.1097/IGC.0b013e318251051a.

PMID:
22635029
17.

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.

del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T.

Gynecol Oncol. 2012 Sep;126(3):369-74. doi: 10.1016/j.ygyno.2012.05.028. Epub 2012 May 30.

PMID:
22659190
18.

Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.

Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.

Oncology. 2013;84(3):158-65. doi: 10.1159/000341366. Epub 2012 Dec 28.

PMID:
23296063
19.

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer.

Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Völker P, Kavanagh J, Steger M, Schulz KD, Emons G.

Gynecol Oncol. 2003 Sep;90(3):552-9.

PMID:
13678723
20.

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.

Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA.

Gynecol Oncol. 2004 Dec;95(3):624-31.

PMID:
15581974

Supplemental Content

Support Center